KAD-1229

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes

Conditions

Type 2 Diabetes

Trial Timeline

โ€” โ†’ Nov 1, 2012

About KAD-1229

KAD-1229 is a phase 3 stage product being developed by Kissei Pharmaceutical for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01333592. Target conditions include Type 2 Diabetes.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01333592Phase 3Completed